Beta Therapeutics

BT logo 2014

Beta Therapeutics is developing new diabetes therapeutics based on key discoveries made at The Australian National University’s John Curtin School of Medical Research.

Beta Therapeutics aims to generate preventative and potentially curative therapies for the 6.4% of the world who suffer from Type 1 or Type 2 Diabetes. Early results generated through Beta Therapeutics’ Discovery Translation Fund project have given ANU Connect Ventures the confidence to support the company to generate a pre-clinical package that will lead to clinical development.



Comments are closed.